Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Cardiac Biomarkers Market: By Biomarker Type: Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Others; By Indication; By End User; By Testing Location; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments

Global Cardiac Biomarkers Market Outlook

The global cardiac biomarkers market reached a value of about USD 9.4 billion in 2021. The market is further estimated to grow at a CAGR of 9.90% in the forecast period of 2022-2027 to reach a value of around USD 15.07 billion by 2027.

 

Expanding Point of Care Testing Facility to Propel the Market Growth of Cardiac Biomarkers

Based on testing location, the point of care segment is expected to witness robust growth in the market of cardiac biomarkers over the forecast period. This could be attributed to the rising inclination towards point of care testing due to its potential to offer high sensitivity diagnosis. The improved patient management owing to rapid turnaround of results in a user-friendly manner without wasting time is accelerating the development of the market. The point of care offers high-quality biomarker measurements for diverse clinical settings, including acute care, outpatient clinics, clinical research centres, homes, rural areas, and the developing world. The point of care testing facilitates rapid treatment decisions and reduces the pressure on emergency departments. They enable widespread access to affordable cardiac diagnostics as it leads to reduction in overall hospital and laboratory facility costs.

 

Market Segmentation

Cardiac biomarkers are used to diagnose critical heart conditions by evaluating the heart functioning of a patient. The biomarkers include enzymes, hormones or proteins that show up in the blood under severe stress or any injury and the test measure these cardiac biomarkers to find the seriousness of heart disease.

The market for cardiac biomarkers, by biomarker type, is divided into:

  • Creatine Kinase -MB (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others

Based on indication, the market is segmented into:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

On the basis of end-user, the market is bifurcated into:

  • Hospitals
  • Speciality Clinics

Based on testing location, the market is divided into:

  • Point of Care
  • Laboratory Testing

The regional markets for cardiac biomarkers can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Increasing Prevalence of Critical Heart Conditions to Drive the Market Growth of Cardiac Biomarkers

The pandemic bolstered the market for cardiac biomarkers due to the impact of COVID 19 on cardiovascular systems, which led to the rising application of biomarkers in diagnosis and treatment. The increasing cases of cardiac diseases worldwide due to unhealthy lifestyle changes are providing impetus to the market development of cardiac biomarkers. As per the World Health Organisation estimates, approximately 17.9 million people died from cardiovascular diseases in 2019, representing 32% of overall global deaths. The growing awareness about the reliable diagnosis that cardiac biomarkers offer to prevent heart diseases and the developing healthcare infrastructure play a critical role in expanding the market of cardiac biomarkers. The government initiatives to improve the diagnosis and treatment of cardiovascular diseases and the rising approvals of biomarker tests by organisations like the United States Food and Drug Administration is also invigorating the market of cardiac biomarkers. The increasing diagnostic tests offered by market players and the rapid development of novel biomarker tests to support clinicians in cardiac risk identification are expected to augment the market over the forecast period.

 

Key Players in the Global Cardiac Biomarkers Market

The report gives a detailed analysis of the following key players in the global cardiac biomarkers market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • F. Hoffmann-La Roche Ltd
  • Beckman Coulter, Inc.
  • Creative Diagnostics
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Biomarker Type
  • Indication
  • End User
  • Testing Location
  • Region
Breakup by Biomarker Type
  • Creatine Kinase -MB (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others
Breakup by Indication
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
Breakup by End User
  • Hospitals
  • Speciality Clinics
Breakup by Testing Location
  • Point of Care
  • Laboratory Testing
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd
  • Beckman Coulter, Inc.
  • Creative Diagnostics
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Industry Opportunities and Challenges  
8    Global Cardiac Biomarkers Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Cardiac Biomarkers Historical Market (2017-2021) 
    8.3    Global Cardiac Biomarkers Market Forecast (2022-2027)
    8.4    Global Cardiac Biomarkers Market by Biomarker Type
        8.4.1    Creatine Kinase -MB (CK-MB)
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Troponins (T and I)
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Myoglobin
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Brain Natriuretic Peptide (BNPs) or NT-proBNP
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2021)
            8.4.4.3    Forecast Trend (2022-2027)
        8.4.5    Ischemia Modified Albumin (IMA)
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2017-2021)
            8.4.5.3    Forecast Trend (2022-2027)
        8.4.6    Others
    8.5    Global Cardiac Biomarkers Market by Indication
        8.5.1    Myocardial Infarction
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Congestive Heart Failure
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Acute Coronary Syndrome
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Atherosclerosis
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Others
    8.6    Global Cardiac Biomarkers Market by End User
        8.6.1    Hospitals
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Speciality Clinics
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
    8.7    Global Cardiac Biomarkers Market by Testing Location
        8.7.1    Point of Care
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2017-2021)
            8.7.1.3    Forecast Trend (2022-2027)
        8.7.2    Laboratory Testing
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2017-2021)
            8.7.2.3    Forecast Trend (2022-2027)
    8.8    Global Cardiac Biomarkers Market by Region
        8.8.1    Market Share
            8.8.1.1    North America
            8.8.1.2    Europe
            8.8.1.3    Asia Pacific
            8.8.1.4    Latin America
            8.8.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    F. Hoffmann-La Roche Ltd
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Beckman Coulter, Inc.
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Creative Diagnostics
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Bio-Rad Laboratories, Inc.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    bioMérieux SA
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Others
13    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Cardiac Biomarkers Market: Key Industry Highlights, 2017 and 2027
2.    Global Cardiac Biomarkers Historical Market: Breakup by Biomarker Type (USD Billion), 2017-2021
3.    Global Cardiac Biomarkers Market Forecast: Breakup by Biomarker Type (USD Billion), 2022-2027
4.    Global Cardiac Biomarkers Historical Market: Breakup by Indication (USD Billion), 2017-2021
5.    Global Cardiac Biomarkers Market Forecast: Breakup by Indication (USD Billion), 2022-2027
6.    Global Cardiac Biomarkers Historical Market: Breakup by End-User (USD Billion), 2017-2021
7.    Global Cardiac Biomarkers Market Forecast: Breakup by End-User (USD Billion), 2022-2027
8.    Global Cardiac Biomarkers Historical Market: Breakup by Testing Location (USD Billion), 2017-2021
9.    Global Cardiac Biomarkers Market Forecast: Breakup by Testing Location (USD Billion), 2022-2027
10.    Global Cardiac Biomarkers Historical Market: Breakup by Region (USD Billion), 2017-2021
11.    Global Cardiac Biomarkers Market Forecast: Breakup by Region (USD Billion), 2022-2027
12.    North America Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2017-2021
13.    North America Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2022-2027
14.    Europe Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2017-2021
15.    Europe Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2022-2027
16.    Asia Pacific Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2017-2021
17.    Asia Pacific Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2022-2027
18.    Latin America Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2017-2021
19.    Latin America Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2022-2027
20.    Middle East and Africa Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2017-2021
21.    Middle East and Africa Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2022-2027
22.    Global Cardiac Biomarkers Market Structure.

Key Questions Answered in the Report

In 2021, the global cardiac biomarkers market attained a value of nearly USD 9.4 billion.

The market is assessed to grow at a CAGR of 9.90% between 2022 and 2027.

The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach almost USD 15.07 billion by 2027.

The major market drivers include the rising importance of cardiac biomarkers in treating heart diseases, developing healthcare infrastructure, and the expansion of point of care facilities.

The key market trends guiding the growth of the market include the increasing cases of heart diseases, government initiatives in approving the biomarker diagnostic tests, and development of novel cardiac biomarker tests by market players.

The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

The significant biomarker types of cardiac biomarkers include Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA), among others.

The various indications of the market, include myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis, among others.

The major end users of the market include hospitals and speciality clinics.

The different testing locations of cardiac biomarkers, include point of care and laboratory testing.

The major players in the market are F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, Bio-Rad Laboratories, Inc., and bioMérieux SA, among others.

Analyst Review

The global cardiac biomarkers market attained a value of nearly USD 9.4 billion in 2021, driven by the increasing cases of critical heart conditions. Aided by the development of cardiac biomarker tests by market players, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 9.90%. The market is estimated to reach about USD 15.07 billion by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The market for cardiac biomarkers, by biomarker type, is divided into Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA), among others. Based on indication, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis, among others. On the basis of end user, the market is classified into hospitals and speciality clinics. Based on testing location, the market is bifurcated into point of care and laboratory testing. The major regional markets for cardiac biomarkers are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, Bio-Rad Laboratories, Inc., and bioMérieux SA, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER